An early feasibility study of the Nativis Voyager
clinical trials; medical device; novel therapy; recurrent GBM; ultra-low radiofrequency energy; brain tumor
AIM: Evaluation of the Nativis Voyager
MATERIALS & METHODS: Voyager is a noninvasive, nonthermal, nonionizing and portable investigational device which delivers ultra-low radio frequency energy (ulRFE
RESULTS: Data from the first 11 patients treated are reported here. Median progression-free survival was 10 weeks in the V arm and 16 weeks in the V + SoC arm. Median overall survival was 16 months in V arm and 11 months in the V + SoC arm. No serious adverse events associated with the device were reported.
CONCLUSION: These data suggest that the Voyager is safe and feasible for the treatment of rGBM.
Neurosciences (Brain & Spine)
Cobbs, Charles; McClay, Edward; Duic, J Paul; Nabors, L Burt; Morgan Murray, Donna; and Kesari, Santosh, "An early feasibility study of the Nativis Voyager" (2018). Articles, Abstracts, and Reports. 918.